Rekha Hemrajani
CIK 1771213 · President and CEO · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$205.3K
Companies
7
Total Filings
30
Lifetime Open-Market Net
$135.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MXCT | Director | 70,314 | $1.05 | $73.8K | -$22.4K | 8 | 2026-06-22 |
| BIOA | Director | 3,000 | $21.92 | $65.8K | $54.0K | 4 | 2026-06-12 |
| LBRX | Director | — | $34.94 | — | $0 | 2 | 2026-06-05 |
| ALXO | Director | 33,000 | $1.99 | $65.7K | $103.4K | 8 | 2026-01-21 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | Director | — | $4.36 | — | $0 | 4 | 2020-06-25 |
| Aravive, Inc. (ARAV) Delisted | President and CEO | 14,250 | $0.04 | $571 | $0 | 2 | 2020-04-09 |
| RCUS | See Remarks | — | $27.05 | — | $0 | 1 | 2019-03-25 |
Recent Filings · Page 3 of 3
30 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-08-11 | MXCT | Grant (A) | — | $0 | EDGAR |
| 2021-06-15 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2020-07-21 | ALXO | Buy (P) | +3,000 | $57.0K | EDGAR |
| 2020-06-25 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-09 | Aravive, Inc. (ARAV) Delisted | Disp (D) | −42,750 | $0 | EDGAR |
| 2020-01-09 | Aravive, Inc. (ARAV) Delisted | Grant (A) | +57,000 | $0 | EDGAR |
| 2019-08-16 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-08-02 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-05-03 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-25 | RCUS | Grant (A) | — | $0 | EDGAR |
Showing 21–30 of 30
Prev
Page 3 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.